# A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06992258/  
OnCo record `nct06992258` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fruquintinib, Trifluridine/tipiracil in colorectal cancer, run by Criterium, Inc., now recruiting.

## Summary

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06992258 by Criterium, Inc., with 120 participants planned, started 2025-10-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06992258
- Phase: 2
- Setting: A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Sponsor: Criterium, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06992258: https://clinicaltrials.gov/study/NCT06992258

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)

---
JSON: https://onco.cc/api/v1/entities/nct06992258.json